PF-Atlas › Clinical Trials › NCT05279040
Trikafta Exercise Study in Cystic Fibrosis
Trikafta · Not specified
Registry ID
NCT05279040
Phase
Not specified
Status
Recruiting
Drug / intervention
Trikafta
Sponsor
University of British Columbia
Start
2021-11-10
Enrollment
20
Locations
1
About this trial
Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05279040 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.